3CL Pharma: Supplements, Drugs & Tests to address Long COVID Symptoms & Hospitalized COVID.

1

CUSTOMER PROVEN: 90% in Long COVID & 94% in Acute COVID benefitted from improved symptoms.

2

DRUG APPROVAL: Tollovir is a Phase 2/3 candidate for hospitalized COVID & Phase 2 for Long COVID.

3

VALUATION REPORT: Third-party valuation of Pharma assets is currently valued at $1.98 Billion.

4

OBSERVATIONAL DATA: Viral persistence theory strongly supports Long COVID trials with Tollovid.

5

PAXLOVID REBOUND: Case studies support use of Tollovid to prevent growing viral rebound market.

6

ORAL ANTIVIRAL: The COVID treatment is likely to become the Standard of Care in hospital setting.

7

COVID TESTING: Rapid TolloTest to detect COVID infection 2-5 days sooner before symptoms start.

8

DEMAND: Our supplement Tollovid is the only 3CL Protease Inhibitor available without a prescription.

3CL Pharma